Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

General Health

Health

Medical Devices

Other Health

Sub-Q Bionics

More Like This

Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care

PR Newswire associated0

YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

PR Newswire associated0

UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence

EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain

PR Newswire associated0

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management